Summary
Background Neisseria gonorrhoeae (gonorrhoea) and antimicrobial-resistant (AMR) gonorrhoea infections disproportionately affect men who have sex with men (MSM). Vaccine development is challenging, but a N. meningitidis (group B) vaccine given to children and young adults was associated with a ca. ~30% reduction in gonorrhoea diagnoses. We investigated the impact of vaccination on N. gonorrhoeae AMR development and transmission in MSM.
Methods We developed a compartmental model of N. gonorrhoeae transmission among MSM. AMR to ceftriaxone was incorporated as a stepwise increases in minimum inhibitory concentrations and eventual resistance (MIC drift). We estimated the impact of a partially protective vaccine (reducing susceptibility; 2-years protection) targeting high sexual activity MSM on AMR and prevalence until 2050. We performed sensitivity analyses assuming different levels of vaccine effectiveness (VE) and other modes of vaccine action.
Findings Gonorrhoea model prevalence was 3·4% (95% credible interval 3·2% – 3·8%) in all MSM, 12·5% (95% credible interval 12·1% – 12·7%) in high sexual activity MSM. A vaccine with 30% VE cannot prevent AMR, even with high uptake or durable protection. However, it increases time to AMR development by several years. For a fixed uptake of 40% a vaccine needs a minimum VE of 90% to prevent AMR development completely. A vaccine providing complete protection to infection for those vaccinated was most effective in reducing population prevalence and preventing AMR.
Interpretation A vaccine that has limited efficacy for the prevention of gonorrhoea could delay AMR development in MSM, providing time for developing new antimicrobials and more efficacious vaccines.
Funding None
Competing Interest Statement
KT receives funding from GlaxoSmithKline to work on modelling gonorrhoea vaccines, outside the submitted work. NL have received a grant from FINDDx that involves mathematical modelling of antimicrobial resistance in Neisseria gonorrhoeae, outside the submitted work. All other authors have no conflicts of interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ACS: The ACS was approved by the Medical Ethics Committee of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (MEC 07/182). GRAS data: Ethical approval for the study was not necessary following Dutch law as the study used routinely collected, anonymous surveillance data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request
